Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy

Figures & data

Table 1. Characterization of different vectors.

Formulations	Blank NLCs	TMZ/NLCs	RGD-TMZ/NLCs
Particle size (nm)	91.4 ± 1.9	93.6 ± 2.1	118.3 ± 2.6
PDI	0.09 ± 0.01	0.10 ± 0.02	0.11 ± 0.02
Zeta potential (mV)	32.5 ± 3.2	23.3 ± 2.7	28.9 ± 2.9
EE (%)	/	85.3 ± 2.3	84.7 ± 3.2
LC (%)	/	7.3 ± 0.9	5.6 ± 0.5

Table 2. Optimization of RGD-TMZ/NLCs.

Quantity of RGD-PEG-DSPE (mg)	0	20	40	60	80	100
Zeta potential (mV)	23.6 ± 2.1	25.1 ± 1.6	27.1 ± 1.4	28.8 ± 2.1	29.1 ± 2.6	28.7 ± 2.3

Figure 1. Drug release profiles of RGD-TMZ/NLCs and TMZ/NLCs.

Figure 2. The cytotoxicity of RGD-TMZ/NLCs and other formulas in U87MG cells.

Figure 3. The in vivo antitumor therapeutic effect was evaluated in U87 MG solid tumors in mice.